Drugs Made In America Acquisition (DMAA) vs Market Technology Acquisition (MTAK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Market Technology Acquisition is the larger company by market cap ($276.0 million vs $263.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | DMAA | MTAK |
|---|---|---|
| Share price | $10.85 | $9.84 |
| Market cap | $263.40M | $275.97M |
| 1-day change | +0.18% | -0.10% |
| P/E ratio (TTM) | 60.28 | — |
| EPS (TTM) | $0.18 | — |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.89 | $10.00 |
| 52-week low | $10.26 | $9.83 |
| Distance from 52-week high | -0.37% | -1.60% |
| Average volume | 21.20K | 33.56K |
| Shares outstanding | 24.28M | 21.21M |
| Sector | Financial Services | Financial Services |
| Industry | Shell Companies | Shell Companies |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Drugs Made In America Acquisition
DMAA stock →Drugs Made In America Acquisition Corp. does not have significant operations.
Financial Services · Shell Companies
About Market Technology Acquisition
MTAK stock →Market Technology Acquisition Corp is a blank check company. The company was incorporated in 2026 and is headquartered in Rhinebeck, New York.
Financial Services · Shell Companies
DMAA vs MTAK FAQ
Which is bigger, Drugs Made In America Acquisition or Market Technology Acquisition?
Market Technology Acquisition (MTAK) is larger, with a market capitalization of $275.97M compared with $263.40M for Drugs Made In America Acquisition (DMAA).
Are Drugs Made In America Acquisition and Market Technology Acquisition in the same industry?
Yes. Both are classified in the Shell Companies industry within the Financial Services sector.